Clinical Evaluation of Rosiglitazone Maleate (BRL49653C) in Patients With Type 2 Diabetes Mellitus (Combination Therapy With SU) - A Placebo-Controlled Double-Blind Study -
Phase of Trial: Phase III
Latest Information Update: 20 Jan 2017
At a glance
- Drugs Rosiglitazone (Primary) ; Sulfonylureas
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline
- 31 Aug 2018 Biomarkers information updated
- 15 Oct 2008 Actual start date changed from Apr 2006 to May 2006 as reported by ClinicalTrials.gov.
- 10 Aug 2007 Status changed from in progress to completed.